The Advantages of Restricted-Access Barrier Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Advantages of Restricted-Access Barrier Systems
Filling machines often are installed in sterile rooms and separated by isolators to prevent contamination. These methods have certain drawbacks, including making interventions more difficult. Restricted-access barrier systems are an alternative that ensures sterility and facilitates interventions.


Pharmaceutical Technology


Appropriate guidelines, manuals, and drafts for isolators are available in the three major pharmaceutical markets: the United States, Europe, and Japan. The recently rewritten FDA guidelines, Annex 1 of the European Union good manufacturing practice guidelines, and the detailed PIC/S recommendations are helpful for the planning and use of an isolator (3, 4, 8). The Japanese admission authority also is presently working on an appropriate document.

Classifications of RABS


Figure 4: Machine in an active RABS. The RABS has its own air-handling system that draws air from the area and through openings below the product transport.
RABS are more than just a safety covering for production machines. Incoming air passes through suspended high-efficiency (of at least HEPA Class H14) filters and is distributed evenly by a sterile manifold. The doors of the RABS are locked, and the gloveports are the only means of access. Users must transfer materials and components by means of special aseptic transfer systems. Air flows out of RABS the same way it does with simple barriers: through openings underneath the doors or through holes in the lower sections of the doors. The air returns to the same room from which it came. In a closed RABS, air is prefiltered and recirculated through ducts.

RABS can be classified as either active or passive systems. A passive RABS does not have its own air recirculation, filtering, or conditioning. Its high-purity air supply comes from the cleanroom. Air flows downward from the ceiling and returns to the surrounding room through openings under the doors. The air from the room returns through air ducts to the room air-handling unit (see Figures 3 and 4).


Figure 5: Machine in a passive closed RABS. Air is recycled from the room air-handling system. A prefilter also is used, which helps prevent contamination of the air-handling system.
An active RABS typically has an air-handling unit directly attached to it. This unit always contains a HEPA filter and provides even air-flow distribution with the help of a sterile air manifold. A cooling system also can be integrated for temperature-critical products. Air-conditioning expenditure is limited because fresh air is drawn from the cleanroom (see Figure 4).


Figure 6: Aseptic powder-filling line in passive closed RABS.
A closed RABS is different. Closed RABS also may be passive systems that use the cleanroom's ventilation system and filter ceiling. The air does not return to the surrounding area, it passes through prefilters and ducts into the room's airconditioning system (see Figure 5). Because closed RABS concepts are used with toxic and dusty product applications, operators must pay special attention to cleaning the return air ducts and changing the prefilters without contaminating them (see Figure 6).

Active closed RABS have air-filtration and air-conditioning systems (see Figure 7), which are needed to keep conditions constant within the aseptic area, especially when air cooling is required.


ADVERTISEMENT

RELATED CONTENT
The Role of Glasses in Aseptic Production: A Detail Often Ignored
Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation
The Effect of Carrier Material on the Measured Resistance of Spores
The Importance of Pre-Use Integrity Testing in Sterilizing Filtration
Radiation Sterilization of Parenterals
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here